# CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct07335497/  
OnCo record `nct07335497` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CR-001 in advanced solid tumours, run by Crescent Biopharma, Inc., now recruiting.

## Summary

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07335497 by Crescent Biopharma, Inc., with 290 participants planned, started 2026-02-17 and due to reach its primary completion in 2029-02. Interventions recorded: CR-001.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07335497
- Phase: 1/2
- Setting: A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Sponsor: Crescent Biopharma, Inc.
- Enrolled: 290

## Sources

- ClinicalTrials.gov NCT07335497: https://clinicaltrials.gov/study/NCT07335497

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07335497.json